Javascript must be enabled to continue!
The Proportional Fee, Transaction Fee and Membership Fee
View through CrossRef
There are in general three types of fees used by platforms: the fixed membership fee, transaction fee and proportional fee. In real-life, all three fees are used by different platforms. Often, the fee charged by the market maker is a combination of the fixed, transaction and proportional fees. We try to offer a rationale for the usage of these fee structures. Compared with the transaction fee, the profit for the platform is higher under the proportional fee. If the consumption value is high enough, then the profit under the membership fee is the lowest. If the value is low enough, then the profit under the membership fee is the highest. If the value is in the middle, then the profit under the membership fee is in the middle as well. However, when we allow free entry of merchants, results are different. The profit of the card network could be lower under the proportional fee than the transaction fee with free entry of merchants. Equilibrium under the proportional fee and the membership fee is the same. Consumer surplus is lower under the transaction fee than the proportional fee and the membership fee. But social welfare could be higher under the transaction fee. We also consider regulation of the fee structure and the optimal fee.
Title: The Proportional Fee, Transaction Fee and Membership Fee
Description:
There are in general three types of fees used by platforms: the fixed membership fee, transaction fee and proportional fee.
In real-life, all three fees are used by different platforms.
Often, the fee charged by the market maker is a combination of the fixed, transaction and proportional fees.
We try to offer a rationale for the usage of these fee structures.
Compared with the transaction fee, the profit for the platform is higher under the proportional fee.
If the consumption value is high enough, then the profit under the membership fee is the lowest.
If the value is low enough, then the profit under the membership fee is the highest.
If the value is in the middle, then the profit under the membership fee is in the middle as well.
However, when we allow free entry of merchants, results are different.
The profit of the card network could be lower under the proportional fee than the transaction fee with free entry of merchants.
Equilibrium under the proportional fee and the membership fee is the same.
Consumer surplus is lower under the transaction fee than the proportional fee and the membership fee.
But social welfare could be higher under the transaction fee.
We also consider regulation of the fee structure and the optimal fee.
Related Results
Technical Analysis in Financial Markets
Technical Analysis in Financial Markets
The efficient markets hypothesis states that in highly competitive and developed markets it is impossible to derive a trading strategy that can generate persistent excess profits a...
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract
Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...
Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Abstract
Background
Chronic pediatric ITP is an autoimmune disorder characterized by increased platelet destruction and suboptim...

